中国再生医学（08158）发布截至2023年9月30日止九个月业绩，收益1.12亿港元，同比下降31.3%；净利润667.7万港元，同比下降36.7%；每股基本盈利2.34港仙。
责任编辑：卢昱君
中国再生医学发布前三季度业绩 净利润667.7万港元同比下降36.7%
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.